Peijia Medical Ltd. (HK:9996)
:9996
Top Page
Peijia Medical Ltd.
(9996)
Select Model
Select Model
Rating:48Neutral
Price Target:
HK$6.00
▼(-7.83% Downside)
Action:UpgradedDate:01/13/26
The score is held down primarily by weak financial performance—ongoing losses and zero free cash flow despite strong revenue growth—while technicals provide partial support due to positive momentum above major moving averages. Valuation is constrained by negative earnings (negative P/E) and no provided dividend yield.
Positive Factors
Revenue Growth
Strong revenue growth indicates increasing market demand and successful product adoption, which can enhance long-term business sustainability.
Negative Factors
Profitability Challenges
Ongoing profitability challenges can hinder reinvestment and growth, affecting the company's ability to achieve sustainable financial health.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Strong revenue growth indicates increasing market demand and successful product adoption, which can enhance long-term business sustainability.
Read all positive factors
Peijia Medical Ltd. (9996) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$4.12B
Dividend YieldN/A
Average Volume (3M)1.88M
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue Growth29.25%
EPS Growth9.02%
CountryHK
Employees1,047
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.22
Shares Outstanding672,060,670
10 Day Avg. Volume1,295,000
30 Day Avg. Volume1,883,282
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)1.23
Price to Sales (P/S)4.07
P/FCF Ratio-8.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$10.33Price Target Upside58.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.03
Revenue Forecast (FY)HK$1.05B
Peijia Medical Ltd. Business Overview & Revenue Model
Company Description
Peijia Medical Limited engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices. Its transcatheter valve therapeutic products include TaurusOne, a transcatheter aortic valve rep...
How the Company Makes Money
Peijia Medical generates revenue primarily through the sale of its interventional medical devices to hospitals and healthcare providers. The company has established a robust distribution network, allowing it to reach a wide customer base both dome...
Peijia Medical Ltd. Financial Statement Overview
Summary
Income Statement
40
Negative
Balance Sheet
55
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 667.66M | 615.48M | 441.13M | 250.83M | 136.53M | 38.66M |
| Gross Profit | 462.38M | 433.62M | 325.37M | 176.20M | 95.65M | 25.22M |
| EBITDA | -167.28M | -176.59M | -348.52M | -359.90M | -546.54M | -190.87M |
| Net Income | -225.18M | -226.58M | -392.52M | -407.81M | -574.22M | -2.07B |
Balance Sheet | ||||||
| Total Assets | 2.60B | 2.69B | 2.67B | 3.32B | 3.16B | 2.88B |
| Cash, Cash Equivalents and Short-Term Investments | 608.50M | 712.52M | 942.92M | 1.74B | 2.30B | 2.46B |
| Total Debt | 322.28M | 253.40M | 221.13M | 131.88M | 7.63M | 9.13M |
| Total Liabilities | 614.64M | 644.11M | 397.88M | 678.86M | 144.48M | 67.99M |
| Stockholders Equity | 1.97B | 2.03B | 2.27B | 2.64B | 3.02B | 2.81B |
Cash Flow | ||||||
| Free Cash Flow | -153.20M | -285.29M | -899.67M | -506.61M | -506.11M | -206.35M |
| Operating Cash Flow | 36.21M | -5.18M | -583.49M | -376.20M | -436.37M | -181.10M |
| Investing Cash Flow | -84.06M | -140.38M | -386.29M | -463.28M | -424.75M | -12.48M |
| Financing Cash Flow | 12.05M | 10.38M | 85.11M | 117.44M | 741.98M | 2.34B |
Peijia Medical Ltd. Technical Analysis
Positive
6.51
Price Trends
6.13
Positive
6.07
Positive
6.64
Negative
Market Momentum
-0.01
Negative
54.56
Neutral
75.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9996, the sentiment is Positive. The current price of 6.51 is above the 20-day moving average (MA) of 5.85, above the 50-day MA of 6.13, and below the 200-day MA of 6.64, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 54.56 is Neutral, neither overbought nor oversold. The STOCH value of 75.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:9996.
Peijia Medical Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | HK$7.66B | 19.30 | 9.39% | 1.88% | 14.56% | 61.60% | |
69 Neutral | HK$6.32B | 31.02 | 11.84% | 1.50% | -5.18% | -9.69% | |
58 Neutral | HK$8.16B | 27.86 | 4.88% | 0.48% | 35.01% | 483.73% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$4.12B | -18.13 | -11.27% | ― | 29.25% | 9.02% | |
46 Neutral | HK$17.58B | -9.88 | -26.71% | ― | -1.04% | 60.66% | |
43 Neutral | HK$3.69B | -218.71 | 0.22% | ― | -4.38% | ― |
* Healthcare Sector Average
HK:9996
Peijia Medical Ltd.
6.14
1.66
37.05%
HK:0853
MicroPort Scientific
9.17
2.61
39.79%
HK:2190
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
23.70
9.58
67.87%
HK:1858
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
13.07
4.43
51.27%
HK:2160
MicroPort CardioFlow Medtech Corp.
2.90
-0.90
-23.68%
HK:2172
MicroPort NeuroTech Limited
10.81
1.72
18.92%
Peijia Medical Ltd. Corporate Events
Peijia Medical Gains NMPA Approval for Innovative Heart Valve System
Dec 11, 2025
Peijia Medical Limited announced that it has received approval from the National Medical Products Administration of China for its TaurusTrio Transcatheter Aortic Valve (TAV) system. This system, designed to treat severe aortic regurgitation, addre...
Peijia Medical’s TaurusNXT® TAVR System Gains NMPA Registration Acceptance
Dec 7, 2025
Peijia Medical Ltd. announced that the National Medical Products Administration of China has accepted the registration application for its TaurusNXT® Non-glutaraldehyde Crosslinked Dry-tissue Transcatheter Aortic Valve Replacement system. Thi...
Peijia Medical CEO Increases Shareholding, Signaling Confidence in Growth
Dec 5, 2025
Peijia Medical Ltd. announced that its CEO and Chairman, Dr. Yi Zhang, has increased his shareholding in the company through a controlled corporation, with the total investment not exceeding HK$15,000,000. This move signals Dr. Zhang’s confi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.